Kakkis Emil D's Form 4 filing
Ultragenyx Pharmaceutical Inc. (RARE) · filed Sep 5, 2024
- Accession no.
- 0000950170-24-103811
- Filed
- Sep 5, 2024
- Trade date
- Sep 3, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market sales total $1.12M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kakkis Emil DCIK 0001248093 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2024 | Common Stock | SSaleDisposed | −20,000 | $55.85 | −$1,117,000 | 2,223,985 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.